About Nivagen Pharmaceuticals
Nivagen Pharmaceuticals is a Healthcare company based in Sacramento (United States) founded in 2009, and was acquired by Pharmaceutical Associates in January 2026. Developer and contract manufacturer of generic drugs, tablets, capsules, ointment and solution. Nivagen Pharmaceuticals has raised $30.97 million across 5 funding rounds from investors including Pharmaceutical Associates, BizCap and Telegraph Hill Partners. The company has 33 employees. Its chief executive, as recorded, is Jay Shukla. Its Indian entity Nivagen Pharma (India) Private Limited reported revenue of βΉ11.21 Cr. Nivagen Pharmaceuticals offers products and services including CDMO Services, Generic Prescription Drugs, Specialty Drugs, and Over-the-Counter Products. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation.
Company details
Nivagen Pharmaceuticals was founded in 2009 and is based in Sacramento, United States. Operations focus on the pharmaceutical sector, where generic drugs are developed and manufactured through contract services. Tablets, capsules, ointments, and solutions form the core product range. The company supports generic drug production for various clients in the healthcare industry.
- Headquarters Sacramento, United States
- Employees 33
- Stage Acquired
- SectorsHealthcare
- Website nivagen.com
- Social LinkedIn
- Acquired by Pharmaceutical Associates (Jan 2026)
- Legal Name Nivagen Pharma (India) Private Limited
- Date of Incorporation 05 Oct, 2018
- Jurisdiction Mumbai, Maharashtra, India
- Indian entity revenue₹11.21 Cr
FY 2024 · +21% YoY
- Indian entity net profit₹1.30 Cr
FY 2024 · 12% margin
- Indian entity EBITDA₹1.82 Cr
FY 2024 · 16% margin
- Total Equity Funding$30.97M (USD)
in 5 rounds
- Latest Funding Round$5M (USD), Series B
Aug 2023
- InvestorsPharmaceutical Associates
& 2 more
- Employee Count33
- Acquired byPharmaceutical Associates
(Jan 2026)
Associated legal entities of Nivagen Pharmaceuticals
Nivagen Pharmaceuticals is associated with 2 registered companies on The Company Check; the primary company is Nivagen Pharma (India) Private Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Nivagen Pharma (India) Private Limited CIN U74999GJ2018FTC172449 | Active | 05 Oct 2018 | Ahmedabad, Gujarat | ₹11.2 Cr | 33 | 2 | View details |
| Nivagen Pharma (India) Private Limited CIN U74999MH2018FTC315351 | 05 Oct 2018 | Mumbai, Maharashtra, India | View details |
Products & Services of Nivagen Pharmaceuticals
Nivagen Pharmaceuticals offers a comprehensive portfolio of products and services, including CDMO Services, Generic Prescription Drugs, Specialty Drugs, and Over-the-Counter Products.
Offers drug development and manufacturing for partners.
Develops and markets affordable generic drugs for North America.
Produces sterile injectables and formulations for institutional use.
Markets non-prescription drugs for everyday consumer needs.
Funding Insights of Nivagen Pharmaceuticals
Nivagen Pharmaceuticals has successfully raised a total of $30.97M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $5 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $30.97M
- Total Rounds 5
- Last Round Series B β $5M
- First Round $10M
(Sep 2017)
- Investors Count 2
All 5 funding rounds of Nivagen Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2023 | $5M | Series B | β | β | β |
| Sep 2022 | $45M | Debt – Conventional | β | β | |
| May 2020 | $15.97M | Series B | β | Telegraph Hill Partners | β |
| Mar 2020 | $8M | Debt – Conventional | β | β | |
| Sep 2017 | $10M | Series A | β | β | β |
3 investors in total: 3 institutional.
Investors in Nivagen Pharmaceuticals
Nivagen Pharmaceuticals has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Pharmaceutical Associates, BizCap and Telegraph Hill Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science, medical device and healthcare companies | thpartners.net | San Francisco, United States | ||
Small & middle market focused investment bank | 2002 | bizcap.com | San Francisco, United States | |
Generic liquid drugs are manufactured by Pharmaceutical Associates. | 1968 | paipharma.com | Greenville, United States |
Investor details for Nivagen Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Nivagen Pharma (India) Private Limited (Nivagen Pharmaceuticals)
Nivagen Pharma (India) Private Limited is the primary company behind Nivagen Pharmaceuticals. The board of Nivagen Pharma (India) Private Limited currently have 2 directors; the longest-serving is Jwalant Shukla, appointed in 2018. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Jwalant Shukla DIN 08249559 | Director | 05 Oct 2018 | 8 yrs 1 mo | Nivagen Pharma (India) Private Limited |
| Parthil Paragbhai Shukal DIN 11466101 | Director | 16 Jan 2026 | 10 mo | Nivagen Pharma (India) Private Limited |
People of Nivagen Pharmaceuticals
24 people are tracked at Nivagen Pharmaceuticals (6 in leadership, 18 in team); the tracked headcount is 33.
| Name | Role | Group |
|---|---|---|
Jay Shukla | CEO & President | Leadership |
Siddharth Mate | General Manager | Leadership |
Gopal S. Patel | Vice President Global Regulatory Affairs | Leadership |
Vishal Narang Ph.d. | Sr.general Manager, Clinical Drug Development | Leadership |
Nirav Patel | Vice President Research And Development | Leadership |
Rob Hart | Director | Leadership |
Meet Kanojia | Quality Assurance Chemist | Team |
Brijesh Pandya | Senior Chemist | Team |
Gautam Gaitonde | Product Development Scientist | Team |
Priyank Patel | Agm- Project Management | Team |
Niravkumar Prajapati | Pharmaceutical | Team |
Meenakshi Shripat Acharya | Regulatiry Affairs Scientist | Team |
Devendra Patel | Regulatory Affairs Executive | Team |
Miten Vyasa | Sr. Executive - Regulatory Affairs | Team |
Punit P. | Manager - Business Development | Team |
Govind Jagadale | Sr. Chemist | Team |
Nidhi Patel | Assistant | Team |
Kailash Rawat | AGM - Global API Sourcing & Procurement | Team |
Jaydeep Patel | Supply Chain Management | Team |
Ronak Gandhi | Sr. Executive | Team |
4 more people are available in the full profile.
Complete people profiles for Nivagen Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Nivagen Pharmaceuticals
Figures of Nivagen Pharma (India) Private Limited, the primary company behind Nivagen Pharmaceuticals, for FY 2024. Revenue was ₹11.21 Cr (+21% year on year). Net profit was ₹1.30 Cr (12% margin). EBITDA was ₹1.82 Cr (16% margin). Revenue has grown at a compounded annual rate of +36% over three years and +104% over five years.
- ₹11.21 CrRevenue · FY 2024 · +21% YoY
- ₹1.30 CrNet profit · 12% margin
- ₹1.82 CrEBITDA · 16% margin
- ₹1 LakhPaid-up capital
- 33Employees (provident fund records)
- +36%Revenue CAGR, 3 years
- +104%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Nivagen Pharma (India) Private Limited are on its company page.
Detailed financial statements for Nivagen Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Nivagen Pharmaceuticals
4 dated milestones of Nivagen Pharmaceuticals across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Nivagen Pharmaceuticals is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Series B, of $5.0M.
- Exit Acquired by Pharmaceutical Associates.
Web traffic of Nivagen Pharmaceuticals
The website of Nivagen Pharmaceuticals (nivagen.com) receives about 8.5K visits a month.
- Monthly visits8.5K
▲ 54.2% vs previous month
Websites whose visitors overlap most with Nivagen Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
cichlidresearch.com | cichlidresearch.com | 100% | #14,672,194 | β | |
| molecularmatrix.com | 99% | 1.5K | #11,523,751 | View details | |
handbiolab.com | handbiolab.com | 95% | #4,240,186 | β | |
| geminibio.com | 94% | 7.9K | #2,451,069 | View details | |
| thermogenesis.com | 88% | View details | |||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 10 similar websites and full traffic analytics for Nivagen Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Nivagen Pharmaceuticals (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nivagen Pharmaceuticals
Complete news archive for Nivagen Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nivagen Pharmaceuticals
Nivagen Pharmaceuticals was founded in 2009 and raised its 1st funding round 8 years after it was founded.
Nivagen Pharmaceuticals is headquartered in Sacramento, United States. It is registered at Sacramento, California, United States.
Jay Shukla is the CEO of Nivagen Pharmaceuticals, as recorded in our data.
Nivagen Pharmaceuticals is a funded company, having raised a total of $30.97M across 5 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Sep 2017.
Nivagen Pharmaceuticals has 33 employees.
The primary company behind Nivagen Pharmaceuticals, Nivagen Pharma (India) Private Limited, reported revenue of βΉ11.21 Cr for FY 2024, up 21% year on year.
Nivagen Pharmaceuticals was founded in 2009 and is based in Sacramento, United States. Operations focus on the pharmaceutical sector, where generic drugs are developed and manufactured through contract services. Tablets, capsules, ointments, and solutions form the core product range. The company supports generic drug production for various clients in the healthcare industry.
Nivagen Pharmaceuticals offers CDMO Services, Generic Prescription Drugs, Specialty Drugs, and Over-the-Counter Products.
Nivagen Pharmaceuticals has 3 investors. Key investors include Pharmaceutical Associates, BizCap, and Telegraph Hill Partners.
Nivagen Pharmaceuticals operates through Nivagen Pharma (India) Private Limited.
Yes. Nivagen Pharmaceuticals was acquired by Pharmaceutical Associates in January 2026.
The legal entities of Nivagen Pharmaceuticals currently have 2 directors, including Jwalant Shukla, Parthil Paragbhai Shukal.

